Key takeaways
- Glutathione is a naturally occurring tripeptide; reduced glutathione is often abbreviated GSH.
- The two oral randomised trials described here measured biomarkers in healthy adults; their findings and durations differed.
- FDA lists glutathione in Category 1 of its 503A nominations, which it calls “Bulk Drug Substances Under Evaluation”.
- Australia’s October 2026 Poisons Standard places glutathione for parenteral use in Schedule 4; the UK’s emc medicines database returned no results for glutathione (21 Nov 2026).
- A COA must be matched to its batch and its tests: purity alone does not establish amount, sterility or freedom from endotoxin.
01What glutathione is
The “glutathione peptide” is one molecule made from three amino acids, not a seller-named blend.
Those amino acids are glutamic acid, cysteine and glycine. The body makes glutathione, and the reduced form, abbreviated GSH, participates in antioxidant and other cellular processes. Glutathione also occurs in an oxidized form, commonly abbreviated GSSG. A study may measure one form, their combined amount or their ratio; these are related but distinct measurements.
That distinction matters when reading product claims. A change in a blood measurement is not the same endpoint as a change in symptoms, disease risk or lifespan. Likewise, a result for an oral preparation cannot simply be assigned to an injectable product. The molecule is the starting point for a question, not the answer to every claim made about it.
For the terminology, see peptide vs protein vs amino acid. This guide focuses on what the cited studies and regulatory documents actually address, rather than treating every use of glutathione as a single intervention.
02The evidence ladder
The highest tier describes the design of a study, not proof that every proposed use works.
| Level | What it can tell us | What it cannot settle alone |
|---|---|---|
| T1: randomized human trial | Randomised trials compared glutathione with placebo; the two oral trials below measured laboratory markers. | Whether another preparation or route produces a clinical benefit. |
| T2: other human evidence | Small or observational studies can raise questions about people and particular outcomes. | A reliable causal effect without an appropriate comparison. |
| T3: animal research | Experiments can investigate a mechanism or a response in an animal model. | Whether the same response occurs in people. |
| T4: laboratory and mechanistic work | Research can examine glutathione’s chemistry and cellular roles. | Whether supplementing it improves a person’s health. |
The two trials below are T1 because they randomized participants and used placebo controls. Both are small, and the outcomes discussed here are biomarkers. A tier is therefore a useful description of the evidence, not a recommendation or a substitute for looking at what was measured. See our evidence grades.
03Two oral studies, two sets of measurements
Allen and Bradley, 2011. This four-week, randomized, double-blind trial enrolled 40 healthy adults; 39 completed it. Researchers compared oral glutathione with placebo and measured markers of oxidative stress and red-blood-cell glutathione. They found no significant differences between groups in those measures. The result is limited to the participants, preparation, duration and endpoints studied.
Richie and colleagues, 2015. In a six-month randomized, double-blind trial, 54 non-smoking adults were included in the reported analysis. Researchers compared two oral glutathione groups with placebo. FDA’s 2022 review describes levels that rose more than with placebo in erythrocytes, plasma, lymphocytes and cheek cells in one glutathione group, and in whole blood in the other. Levels returned to baseline after a one-month washout.
The second trial’s outcome was a set of glutathione measurements, not evidence that participants lived longer or avoided disease.
The studies differed in length and measurements, so their results should not be compressed into either “oral glutathione always works” or “it never works.” Neither trial establishes the effects of a particular injectable product. Read the outcome and the comparison before applying a headline to another setting.
04Status by country
Checked against the documents below on 21 November 2026. Product, route, claims and intended use matter.
| Country | What the document says | What it does not establish |
|---|---|---|
| United States | FDA’s 503A nominations list, updated 14 May 2026, places glutathione in Category 1: bulk substances under evaluation. | FDA calls Category 1 “Bulk Drug Substances Under Evaluation”; it lists substances, not products. |
| Australia | The October 2026 Poisons Standard lists glutathione for parenteral use in Schedule 4, the prescription-only schedule. | We draw no conclusion of our own about other forms. |
| United Kingdom | The emc medicines database | No search results for glutathione (21 Nov 2026); it is not the full UK register. |
FDA’s 503A page describes an interim policy for Category 1 substances, with conditions for the compounders it covers. These are dated documents and searches, not legal conclusions.
See the broader guides to US, Australian and UK peptide rules. This summary is not legal advice.
05What a COA should show
A certificate of analysis is a report about a tested sample. It is not, by itself, proof that a product is suitable for a particular use.
- Identity and form: the named material, including whether it is reduced glutathione, and a method capable of checking identity.
- Batch and lab: the sample or lot number, testing laboratory, dates and enough information to match the report to the material in question.
- Amount and purity: an assay result with units and limits, plus an impurity profile and the method used. A percentage purity is not automatically the amount in a container.
- Contamination tests where relevant: results, methods and acceptance limits for applicable contaminants. Sterility and bacterial endotoxin are separate questions; one test does not replace the other.
Ask whether the report covers the finished product or only an incoming ingredient. A report for an upstream powder cannot establish the identity, amount or cleanliness of every finished vial made from it. It also cannot tell you what happened after sampling, or establish clinical safety.
FDA has described an analytical method for glutathione and several associated impurities. In an August 2026 alert, it warned compounders not to use dietary-supplement-grade glutathione to make injectable drugs and cautioned that testing alone does not ensure quality. See how to read a COA and how to vet a peptide supplier.
06Safety, uncertainty and the next question
In its 27 August 2026 alert, FDA reported at least 30 patients with adverse events after IV glutathione alone or with other ingredients. It identified a dietary-supplement-grade ingredient used by multiple compounding pharmacies and said two Texas pharmacies had recalled injectable products over elevated endotoxin levels. Some reported events resulted in hospitalization.
That alert concerns particular compounded products and an identified ingredient supply; it does not show that every glutathione product caused those events. It does show why a molecule’s identity, an oral trial and an impurity percentage cannot answer the separate question of injectable-product quality. For anything about your health, a doctor who knows you is the right call.
Why one test cannot stand in for another: endotoxin and sterility testing.
This guide summarizes the cited studies and public documents as checked on 21 November 2026. It is not medical or legal advice.